Welcome to our dedicated page for Eledon Pharmaceuticals SEC filings (Ticker: ELDN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking a clinical-stage biotech means wading through pages of trial data, licensing clauses, and equity financings. Eledon Pharmaceuticals’ disclosures can feel like a second lab notebook. If you have ever searched for “Eledon Pharmaceuticals SEC filings explained simply,” you already know how hard it is to connect CD40L trial milestones to financial risk. Stock Titan removes that friction by turning every filing into a clear, actionable brief.
Each document that hits EDGAR appears here within seconds, paired with an AI summary that highlights what matters. Need the latest “Eledon Pharmaceuticals annual report 10-K simplified”? Our platform unpacks R&D spend, cash runway, and clinical timelines in plain language. Preparing for the next call and want an “Eledon Pharmaceuticals quarterly earnings report 10-Q filing”? Revenue burn, trial costs, and liquidity ratios are extracted automatically. Real-time alerts for “Eledon Pharmaceuticals insider trading Form 4 transactions” ensure you see every officer’s move the moment it is filed.
- “Eledon Pharmaceuticals Form 4 insider transactions real-time” – instant email and mobile push.
- “Eledon Pharmaceuticals proxy statement executive compensation” – clear tables link pay to trial progress.
- “Eledon Pharmaceuticals 8-K material events explained” – AI flags trial pauses, financings, or FDA feedback that can move the market.
- “Eledon Pharmaceuticals earnings report filing analysis” – side-by-side views of quarter-over-quarter burn and runway.
- “Understanding Eledon Pharmaceuticals SEC documents with AI” – dashboards built for biotech investors.
- “Eledon Pharmaceuticals executive stock transactions Form 4” – sortable by officer, date, and option strike.
Stop combing through dense PDFs. Our AI-powered analysis surfaces how each disclosure affects tegoprubart’s path forward, so you can make informed decisions faster.
Eledon Pharmaceuticals (ELDN) reported continued clinical-stage activity focused on tegoprubart, with increased clinical and manufacturing spending to support Phase 1b, Phase 2 BESTOW and a Phase 2 open-label extension. The company disclosed material risk factors including a short operating history, sustained operating losses, the need for additional financing, and potential dilution from multiple warrant and equity programs. Share structure updates and equity programs are described, including a $75.0 million ATM shelf (not yet used), recent registered and private offerings with pre-funded warrants, and designated preferred share series. The report emphasizes reliance on CROs and CMOs, regulatory and enrollment risks, and increased personnel and professional costs tied to expanded development activity.
Eledon Pharmaceuticals (ELDN) reports continued clinical-stage operations focused on tegoprubart and related development programs. The company operates as a single reporting segment with the chief executive officer as the CODM. It has incurred significant operating losses and states it will require additional funding to complete development of its lead candidate. Recent activity increased expenses: a $4.0 million rise tied to kidney transplantation programs, $0.9 million higher manufacturing costs, $0.7 million higher personnel costs and $0.7 million higher stock-based compensation. The company established an "at-the-market" equity program for up to $75.0 million (Shelf effective October 2, 2024) but has not sold shares under it as of March 31, 2025. Capital structure disclosures include 59,881,775 common shares outstanding at March 31, 2025 and several series of non-voting convertible preferred stock and pre-funded warrants outstanding.
Eledon Pharmaceuticals (ELDN) amended its Form 10-K to disclose extensive risk factors, financing arrangements, clinical development progress for tegoprubart, and accounting matters. The company reports increased R&D spending—notably a $15.5 million rise in kidney transplantation programs and higher manufacturing and personnel costs—driven by Phase 1b, Phase 2 BESTOW and Phase 2 open-label extension trials. It described equity financings including pre-funded warrants, common warrants, a 2024 offering and a $75.0 million at-the-market shelf (no shares sold under the ATM as of year-end). The filing reiterates significant liquidity needs, ongoing operating losses, potential dilution from warrant and stock issuances, regulatory and clinical risks, and certain accounting conclusions about preferred stock and warrant classification.
Date: August 6, 2025.
Eledon Pharmaceuticals, Inc. (ELDN) disclosed updated data from its ongoing Phase 1b open-label trial of tegoprubart for the prevention of organ rejection in kidney transplant patients. The results were presented at the World Transplant Congress in San Francisco, CA. The company issued a press release (attached as Exhibit 99.1) and hosted a conference call on the same date. The presentation for the call will be posted on the company investor site at https://ir.eledon.com/investor-relations prior to the call.
The filing notes that the Item 7.01 disclosure and Exhibit 99.1 are not deemed "filed" under Section 18 of the Exchange Act and are not incorporated by reference into Securities Act or Exchange Act filings unless expressly stated.
FAQ
What is the current stock price of Eledon Pharmaceuticals (ELDN)?
What is the market cap of Eledon Pharmaceuticals (ELDN)?
